Which listed company produces Opicapone capsules?

The main manufacturer of Opicapone (Opicapone) capsules is the Portuguese company Bial-Portela. Bial-Portela is a pharmaceutical company with significant R&D capabilities in neuroscience and cardiovascular fields, committed to developing innovative medicines to improve patients' quality of life. As an important research and development result of the company, Opicapone is a long-acting, new-generation catechol-O-methyltransferase transferase (COMT) inhibitor. It is mainly used to treat the motor symptoms of patients with Parkinson's disease, especially those who have experienced dose exhaustion and cannot stably control symptoms.

Bial-Portela has invested a lot of resources in the research and development process of Opicapone and has successfully conducted multiple clinical trials around the world to verify the effectiveness and safety of the drug. As Opicapone has been approved for marketing in Europe, the United States, Japan and other regions, it has become an important choice in the treatment of Parkinson's disease. However, Opicapone capsules have not yet been sold in the Chinese market.

In terms of use, Opicapone is administered in the form of oral capsules, and patients should take it at least1 hour before or 1 hour after a meal. It is important that patients take the medication exactly as directed by their doctor, neither taking more nor less. Even if your symptoms improve significantly, you should continue to take Opicapone as directed by your doctor. Abrupt discontinuation of medication without medical advice may result in severe withdrawal symptoms, including fever, muscle stiffness, abnormal movements, and confusion. Therefore, if your medication needs to be adjusted, your doctor may recommend gradually reducing the dose of Opicapone and adjusting the dosage of other Parkinson's disease medications accordingly.